This study demonstrated that the treatment of CMHE led to the suppression of the development of human BC cells by inducing cell cycle arrest at G0/G1 and apoptotic cell death via the suppression of the Cyclin D1/CDK4-Rb pathway, generating the anti-BC activity of CMHE. Here, RB1 is linked to breast cancer.